The Journal of Immunology, 1998, 161: 3575-3581.
Copyright © 1998 by The American Association of Immunologists
In Vivo and In Vitro Activities of the gp130-Stimulating Designer Cytokine Hyper-IL-61
Malte Peters,
Guido Blinn,
Fian Solem,
Martina Fischer,
Karl-Hermann Meyer zum Büschenfelde and
Stefan Rose-John2
First Department of Medicine, Division of Pathophysiology, University of Mainz, Mainz, Germany
 |
Abstract
|
|---|
IL-6 is a multifactorial cytokine mediating acute inflammatory
responses in the liver. When IL-6 binds to a specific receptor (IL-6R),
the IL-6/IL-6R complex associates with the signal transducer gp130,
initiating intracellular signaling. A soluble form of the IL-6R
(sIL-6R) renders target cells sensitive to IL-6 that do not express the
IL-6R on their surfaces. A designer cytokine, termed Hyper-IL-6,
consisting of IL-6 covalently linked to the sIL-6R was fully active on
gp130-expressing cells at 100- to 1000-fold lower concentrations than
unlinked IL-6 and IL-6R. Mice were injected i.p. with Hyper-IL-6 or
IL-6. Upon injection of Hyper-IL-6 into mice, the acute phase response,
as measured by haptoglobin mRNA expression in the liver, was markedly
increased and lasted significantly longer compared with that in mice
injected with a 10-fold higher dose of IL-6 alone. On human hepatoma
cells, Hyper-IL-6 caused similar effects, indicating that the longer
lasting response to the fusion protein could not only be explained by
the longer plasma half-life of the fusion protein. Experiments using
iodinated IL-6 and Hyper-IL-6 revealed that Hyper-IL-6 bound with high
affinity to gp130 and was less efficiently internalized. This effect
might explain the longer lasting activity of this protein on cells. The
highly active IL-6/sIL-6R designer protein might be of significant
clinical importance for the stimulation of cells that are more
responsive to the IL-6/sIL-6R complex than to IL-6 alone. Such cells
include hemopoietic progenitor cells and
hepatocytes.
 |
Introduction
|
|---|
The
cytokines IL-6, IL-11, LIF,3
CNTF, OSM, and CT-1 are grouped into the IL-6 family of cytokines (1).
The biologic action of these cytokines is mediated by multisubunit,
cell surface receptors that share a common signaling subunit, the gp130
signal transducing molecule (1, 2). The subunits of these receptors are
members of the cytokine/growth hormone receptor family that have
conserved cysteine and tryptophan residues in the extracellular domain
and that signal via the JAK/STAT pathway (1, 3, 4, 5). IL-6 and IL-11 use
a gp130 homodimer, and OSM, CNTF, LIF, and CT-1 use a heterodimer of
gp130 and the 190-kDa LIF receptor for the activation of intracellular
signaling cascades (1, 6). A very early event is tyrosine
phosphorylation of the 92-kDa STAT3 protein by JAK1 or JAK2 kinase (7, 8).
The receptor signaling complexes for CNTF, IL-6, IL-11, and probably
CT-1 (1, 9) contain an additional ligand-specific subunit that is not
required for LIF and OSM binding. Recently, an additional OSM-specific
receptor has been identified that forms a heterodimer with gp130 (10).
The specific ligand binding receptor proteins have been identified in
membrane-bound and soluble (s) forms. In contrast to other soluble
receptors, such as sTNF-R, sIL-1R, and sIL-4R, that antagonize the
actions of their ligands, the soluble receptors for the cytokines of
the IL-6 family act agonistically upon binding, i.e., they stimulate
gp130-expressing cells that on their own would not be able to respond
to the cytokines (11). Cells responsive to the combination of IL-6 and
sIL-6R but not to IL-6 alone include hemopoietic progenitor cells,
endothelial cells, and neuronal cells (12, 13, 14, 15). The number of gp130
molecules on hepatocytes seems to exceed the number of IL-6R molecules,
since the presence of the sIL-6R leads to a dramatic sensitization
toward IL-6 (16). The physiologic importance of activation of the gp130
receptor subunit on various cells has recently been demonstrated in
vitro and in vivo for hemopoietic progenitor cells (15, 17) and in the
process of liver regeneration (18).
We have recently designed a fusion protein consisting of human IL-6 and
the human sIL-6R connected by a flexible peptide chain and have
demonstrated that this protein, termed Hyper-IL-6, is highly active on
gp130-expressing cells in vitro (17). To test the function of this
protein in vivo, we injected Hyper-IL-6 into mice and compared the
resulting acute phase response induction with the respective effects of
IL-6 alone. We demonstrate in this report that the yeast-derived
designer cytokine is fully active in vivo, has a 100-fold increased
biologic activity compared with IL-6, and acts markedly longer than
IL-6. Using iodinated proteins, we show that impaired internalization
of Hyper-IL-6 might account for these effects.
 |
Materials and Methods
|
|---|
Reagents
Human haptoglobin cDNA was a gift from Dr. D. Samols (Cleveland,
OH). Recombinant human (rh) IL-6 was prepared as described (19).
Hyper-IL-6 was prepared as recently described (17). The human IL-6
ELISA kit was obtained from CLB (Amsterdam, The Netherlands) and was
used to measure human IL-6 and Hyper-IL-6 in murine serum. Values
obtained for Hyper-IL-6 were multiplied by 3, since the molecular mass
of Hyper-IL-6 (
60 kDa) was threefold higher than that of IL-6 (
20
kDa).
Cell culture
Human hepatoma cells (HepG2) were grown in DMEM at 5%
CO2 in a water-saturated atmosphere. All cell culture media
were supplemented with 10% FCS, 100 mg/l streptomycin, and 60 mg/l
penicillin.
Animal treatment
Mice were maintained in a 12-h light, 12-h dark cycle under
standard conditions and were provided food and water ad libitum.
Procedures involving animals and their care were conducted in
conformity with national and international laws and policies. The
rhIL-6 and Hyper-IL-6 were injected i.p. at the doses indicated in the
figures.
Extraction of total RNA and Northern (RNA) blot analysis
Mice were killed by cervical dislocation, and total RNA was
isolated from the liver by the phenol/chloroform method (20). From
cells, total RNA was prepared using the RN-Easy preparation kit
(Qiagen, Chatsworth, CA). Five micrograms of heat-denatured RNA per
sample was fractionated on a 1% agarose gel with 7% formaldehyde. The
separated RNA was transferred to GeneScreen Plus membranes (DuPont-New
England Nuclear, Dreieich, Germany) according to the manufacturers
instructions. The filters were prehybridized at 68°C for 2 h in
10% dextran sulfate, 1 M NaCl, and 1% SDS and hybridized in the same
solution with [32P]cDNA fragments labeled by random
priming (21). A 0.9-kb HinfI restriction fragment of human
haptoglobin cDNA and a 1.3-kb EcoRI/HinfI
fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used
as probes. The hybridized filters were washed under stringent
conditions and exposed to x-ray films (XAR-5, Eastman Kodak, Rochester,
NY).
Haptoglobin ELISA
Stimulation of HepG2 cells was measured as the secretion of the
acute phase protein haptoglobin analyzed by ELISA, as recently
described (22).
Iodination of IL-6 and Hyper-IL-6
The rhIL-6 and yeast expressed Hyper-IL-6 were iodinated
according to the procedure of Markwell (23) with modifications as
previously described (24).
Binding studies
HepG2 cells were grown to confluence using 24-multiwell plates
(Nunc, Dreieich, Germany). After confluence was reached (
5 x
105 cells/well), cells were washed twice with ice-cold
binding medium (DMEM containing 0.2% (w/v) BSA). Binding was initiated
by the addition of [125I]rhIL-6 or
[125I]Hyper-IL-6 at a concentration of 100 pM for 4
h at 4°C in the presence of increasing amounts of unlabeled rhIL-6 or
Hyper-IL-6, respectively (0.11000 nM). After 4 h, medium was
removed, and the cells were washed three times with PBS containing 1 mM
MgCl2, 0.1 mM CaCl2, and 0.2% BSA. Cells were
subsequently lysed in 1 ml of 1 M NaOH, and radioactivity was measured
in a gamma counter. Binding affinities were calculated by nonlinear
regression using the computer program PrismGraph (GraphPad, San Diego,
CA). All experiments performed in duplicate were repeated three times.
Internalization studies
In a total volume of 1 ml of ice-cold binding medium, HepG2
cells that had been grown to confluence in 35-mm dishes were preloaded
with 1 nM [125I]rhIL-6 or [125I]Hyper-IL-6
at 4°C for 2 h. Internalization was initiated by warming the
cells to 37°C. Surface-bound [125I]rhIL-6 or
[125I]Hyper-IL-6 was determined after different periods
of incubation after subjecting the cells to 0.5 M NaCl/HCl, pH 1, for 3
min followed by an additional wash with PBS containing 0.2% BSA.
Internalization of [125I]rhIL-6 or
[125I]Hyper-IL-6 was determined after lysis of the cells
in 1 ml of 1 M NaOH. All experiments performed in duplicate were
repeated three times.
 |
Results
|
|---|
The designer protein Hyper-IL-6 is a stronger stimulator of the
hepatic acute phase response in vivo than IL-6
One major activity of IL-6 is the induction of the hepatic acute
phase response (25). We therefore analyzed the induction of the acute
phase response gene expression in the livers of NMRI mice injected i.p.
with IL-6 or Hyper-IL-6. In time-course experiments the mice were
injected with either 40 µg of IL-6 or 4 µg of Hyper-IL-6 per mouse.
Following i.p. injection, mice were killed by cervical dislocation at
the different time points as indicated in the figures. RNA was prepared
from the livers and subjected to Northern blot analysis. As can be seen
in Figure 1
A, when 40 µg of
IL-6 was injected into NMRI mice, the peak haptoglobin mRNA expression
was detected 4 to 6 h after injection, declined after 8 h,
and returned to the baseline after 24 h. Upon injection of only
1/10th (4 µg) of the designer protein Hyper-IL-6 (Fig. 1
B), however, haptoglobin mRNA expression increased for
12 h and peaked 12 to 24 h after injection. Most importantly,
48 h after injection, there was still considerable haptoglobin
mRNA expression, and only at 72 h after injection did the mRNA
return to baseline values. Of note, haptoglobin mRNA expression in
animals receiving Hyper-IL-6 was much stronger than that in mice
receiving IL-6. These experiments demonstrate that the designer protein
tested in this study is active markedly longer, especially considering
the fact that Hyper-IL-6 was injected at a 10-fold lower dosage than
IL-6.

View larger version (70K):
[in this window]
[in a new window]
|
FIGURE 1. Time course of induction of haptoglobin mRNA expression by IL-6 and
Hyper-IL-6. Haptoglobin mRNA expression was analyzed in NMRI mice
injected i.p. with 40 µg of IL-6/mouse (A) or with 4
µg of Hyper-IL-6/mouse (B). Mice were sacrificed at
the time points indicated. RNA was prepared from the liver and
subjected to Northern blot analysis. Filters were hybridized with a
32P-labeled 0.9-kb HinfI restriction
fragment of human haptoglobin cDNA. The lower panels in
A and B represent photographs of the
ethidium bromide-stained RNA gel to demonstrate equal loading of
RNA.
|
|
As shown in Figure 2
, the two proteins
were injected at increasing concentrations into NMRI mice.
Mice were sacrificed after 4 h, and RNA was prepared from the
livers and subjected to Northern blot analysis. The first appreciable
induction of the haptoglobin mRNA by IL-6 was detected at a dose of 0.4
µg/mouse (Fig. 2
A). By contrast, Hyper-IL-6 induced a
comparable haptoglobin mRNA induction at a dose of 0.004 µg/mouse
(Fig. 2
B). The level reached after injection of 0.4
µg/mouse Hyper-IL-6 was comparable to the induction reached with 40
µg/mouse of IL-6. No change in mRNA content occurred for the
constitutively expressed GAPDH gene. Therefore, in mice, Hyper-IL-6
showed a 100-fold higher activity of induction of the acute phase
protein haptoglobin than did IL-6.

View larger version (34K):
[in this window]
[in a new window]
|
FIGURE 2. Dose response of induction of haptoglobin mRNA expression by IL-6 and
Hyper-IL-6. Haptoglobin and GAPDH mRNA expressions were analyzed in
NMRI mice injected i.p. with various dosages of IL-6 (A)
or Hyper-IL-6 (B) as indicated. Mice were sacrificed
4 h after injection. RNA was prepared from the liver and subjected
to Northern blot analysis. Filters were hybridized with a
32P-labeled 0.9-kb HinfI restriction
fragment of human haptoglobin cDNA and with a 32P-labeled
1.3-kb HifI restriction fragment of GAPDH.
|
|
The designer protein Hyper-IL-6 circulates longer and with higher
plasma levels than IL-6
To investigate the fate of injected IL-6 or Hyper-IL-6 in vivo, we
determined human IL-6 and Hyper-IL-6 serum levels using a human IL-6
ELISA. Figure 3
A demonstrates
the corresponding serum levels of the mice analyzed in Figure 1
, A and B. In mice injected with 40 µg of IL-6,
IL-6 serum levels peaked at 2 h following injection and were
detectable only 8 h following injection. Upon injection of 4 µg
of Hyper-IL-6, however, Hyper-IL-6 serum levels peaked 1 to 3 h
following injection and were detectable as long as 48 h. This
experiment showed that the designer protein Hyper-IL-6 circulated for a
significant longer time in the serum in vivo. In Figure 3
, B
and C, the corresponding serum levels of the mice analyzed
in Figure 2
are presented. While the injection of 0.4 µg of IL-6 did
not result in the detection of IL-6 in the serum 4 h after
application (Fig. 3
B), the same dose of Hyper-IL-6 yielded a
significant amount of Hyper-IL-6 circulating in the serum after the
same period of time (Fig. 3
C). When the doses of 4 µg of
IL-6 and 4 µg of Hyper-IL-6 were compared, the latter caused serum
levels of 45 ng/ml compared with 1.5 ng/ml for IL-6. These data
demonstrate that injection of Hyper-IL-6 led to 30-fold higher serum
concentrations in the circulation compared with IL-6.
The designer cytokine Hyper-IL-6 is active longer in vitro
The observed longer activity of Hyper-IL-6 in vivo could be due to
the increased plasma half-life of the fusion protein compared with that
of IL-6. If this would be the case, the extended time course of
activity of Hyper-IL-6 should not be observed in cell culture
experiments in vitro. HepG2 cells were stimulated in a time-course
experiment with 10 ng/ml of IL-6 and Hyper-IL-6. In cells stimulated
with IL-6, the peak induction of haptoglobin mRNA was found at 24
h after stimulation and declined thereafter (Fig. 4
A). When Hyper-IL-6 was used,
haptoglobin mRNA expression peaked at 48 h following stimulation
and lasted longer than 72 h (Fig. 4
B). No change in
mRNA content occurred for the constitutively expressed GAPDH gene. When
different concentrations of IL-6 and Hyper-IL-6 were tested on HepG2
cells, and haptoglobin secretion was measured by ELISA, Hyper-IL-6 at 1
ng/ml induced haptoglobin levels reached after 10 ng/ml of IL-6
stimulation (Fig. 4
C). Stimulation with 10 and 100 ng/ml
Hyper-IL-6 led to higher haptoglobin levels, exceeding those obtained
after stimulation with 100 ng/ml.

View larger version (30K):
[in this window]
[in a new window]
|
FIGURE 4. Stimulation of HepG2 cells with IL-6 and Hyper-IL-6. Time course
(A and B) and dose-response studies
(C) of induction of haptoglobin and GAPDH mRNA
expression in human hepatoma (HepG2) cells by IL-6 and Hyper-IL-6. For
the time-course experiment, cells were treated for the time periods
indicated with 10 ng/ml of IL-6 (A) or Hyper-IL-6
(B), respectively. Total RNA was prepared and subjected
to Northern blot analysis for haptoglobin and GAPDH expression. For the
dose-response experiment (C), cells were treated with
increasing amounts of IL-6 (white bars) or Hyper-IL-6 (black bars),
respectively. Concentrations of IL-6 and Hyper-IL-6 are given in
nanograms per milliliter. Stimulation of HepG2 cells was measured as
the secretion of the acute phase protein haptoglobin analyzed by ELISA
as recently described (22). Total RNA was prepared and subjected to
Northern blot analysis for haptoglobin and GAPDH mRNA expression.
|
|
Since IL-6 and Hyper-IL-6 are stable for days in medium containing 10%
FCS (data not shown), we speculated that the extended time course of
Hyper-IL-6 could be caused by decreased cellular uptake or increased
binding affinity of the fusion protein Hyper-IL-6. We investigated
whether the Hyper-IL-6-induced biologic activity could be abolished by
washing the cells with cytokine-free medium 24 h after stimulation
(Fig. 5
). Five 10-cm cell culture dishes
were cultured with HepG2 cells to 60% confluence and were incubated
for 24 h with Hyper-IL-6 (10 ng/ml). After 24 h RNA was
prepared from one dish to document the haptoglobin mRNA concentration
(Fig. 5
, lane 1). At the same time point, two of the
remaining dishes were washed three times with PBS at 37°C, and the
medium was replaced with cytokine-free medium. The two other dishes
were left unwashed, and incubation was continued in the presence of
Hyper-IL-6. At 24 and 48 h, respectively, RNA was prepared from
washed (lanes 4 and 5) and unwashed
(lanes 2 and 3) cells. It can be seen in
Figure 5
that washing of HepG2 cells had no significant influence on
haptoglobin mRNA expression 48 and 72 h poststimulation. No change
in mRNA content occurred for the constitutively expressed GAPDH gene.

View larger version (30K):
[in this window]
[in a new window]
|
FIGURE 5. Hyper-IL-6 stimulation is resistant to washing. HepG2 cells were
treated with 10 ng/ml of Hyper-IL-6. Twenty-four hours after
stimulation, cells were either left untreated with the original medium
containing the respective cytokine (lanes 2 and
3) or were subjected to intensive washing at 37°C with
PBS followed by incubation with cytokine-free medium (lanes
4 and 5). Forty-eight and seventy-two hours
poststimulation, RNA was prepared from the cells and subjected to
Northern blot analysis for human haptoglobin and GAPDH mRNA expression.
Filters were hybridized with a 32P-labeled 0.9-kb
HinfI restriction fragment of human haptoglobin cDNA and
with a 32P-labeled 1.3-kb HifI restriction
fragment of GAPDH.
|
|
Biologic activity and stability in vivo of radiolabeled cytokines
For binding and internalization measurements of IL-6 and
Hyper-IL-6, iodinated cytokines were needed. IL-6 and Hyper-IL-6 were
iodinated using 125I-labeled Bolton-Hunter reagent. To
demonstrate that radiolabeled and unlabeled IL-6 and Hyper-IL-6 had
equal biologic activities, murine B9 cells (26) and BAF/3 cells stably
transfected with the human gp130 cDNA (27) were used. Murine B9 cells
were stimulated with different concentrations of
[125I]IL-6 and unlabeled IL-6 (Fig. 6
A). BAF/3-gp130 cells were
stimulated with different concentrations of
[125I]Hyper-IL-6 and unlabeled Hyper-IL-6 (Fig. 6
B). Proliferation was measured after 72 h using the
3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide
proliferation assay. It can be seen in Figure 6
that no difference with
respect to biologic activity of radiolabeled or unlabeled IL-6 and
Hyper-IL-6 could be demonstrated on BAF/3-gp130 cells or on murine B9
cells.

View larger version (21K):
[in this window]
[in a new window]
|
FIGURE 6. Activity and stability in vivo of radiolabeled cytokines on BAF/3-gp130
cells. Murine B9 cells were used to compare the bioactivity of
radiolabeled [125I]IL-6 with that of unlabeled IL-6
(A). BAF/3 cells stably transfected with the human gp130
cDNA (27) were used to compare the bioactivity of radiolabeled
[125I]Hyper-IL-6 with that of unlabeled Hyper-IL-6
(B). The proliferation of cells treated with IL-6/sIL-6R
or Hyper-IL-6 at the concentrations indicated was measured after
72 h using the
3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide
proliferation assay. Data are given as the mean proliferation (±SD) of
three independent experiments. To investigate the stability of the
designer protein, radiolabeled [125I]Hyper-IL-6 (10.000
cpm/well; 100 µl/well) was incubated with HepG2 cells in a 96-well
plate in DMEM containing 10% FCS at 37°C (C). At the
time points indicated in the figure, supernatant was harvested from the
HepG2 cells. Ten microliters of cell supernatant, respectively, were
loaded onto a 12.5% SDS gel and subjected to autoradiography. The
arrow marks the 55-kDa Hyper-IL-6 protein. C, Five
hundred counts per minute of radiolabeled
[125I]Hyper-IL-6.
|
|
To investigate the stability of the designer protein, radiolabeled
[125I]Hyper-IL-6 (10,000 cpm/well) was used on HepG2
cells in a 96-well plate in DMEM containing 10% FCS at 37°C (Fig. 6
C). After the time points indicated in Figure 6
, supernatant was harvested from the HepG2 cells. It is evident that the
fusion protein is not degraded in vitro in the presence of FCS. It can
be concluded from these data that proteases present in serum are not
capable of cleaving the flexible polypeptide linker that was used to
connect one molecule of IL-6 with one molecule of sIL-6R.
Binding and internalization of IL-6 and Hyper-IL-6
A plausible explanation for the fact that Hyper-IL-6 could not be
washed away, as demonstrated in Figure 5
, was that binding of
Hyper-IL-6 to the gp130 signal transducing molecule was tight and could
not be reversed by washing the cells with medium.
Using [125I]IL-6 and [125I]Hyper-IL-6, we
performed competitive binding studies to measure the affinities of the
cytokines for their respective receptors. Binding curves are shown in
Figure 7
, A and B.
From these curves, a Kd value for IL-6 of
3.09 x 10-9 M was calculated, which is reasonably
close to the low affinity binding of IL-6 to the membrane-bound IL-6R
(28). For Hyper-IL-6, a Kd value of 5.936
x 10-11 M was calculated, in line with the high affinity
binding for the IL-6/sIL-6R complex, which has been reported to range
from 1.5 x 10-11 on HepG2 cells (29).

View larger version (15K):
[in this window]
[in a new window]
|
FIGURE 7. Competition of binding of [125I]IL-6 and
[125I]Hyper-IL-6 to HepG2 cells. Cells were washed twice
with ice-cold binding medium (DMEM containing 0.2% (w/v) BSA). Binding
was initiated by the addition of [125I]IL-6
(A) or [125I]Hyper-IL-6 (B)
at the concentration of 100 pM for 4 h at 4°C in the presence of
increasing amounts of unlabeled IL-6 or Hyper-IL-6, respectively, as
indicated. After 4 h, medium was removed, and the cells were
washed three times with PBS containing 1 mM MgCl2, 0.1 mM
CaCl2, and 0.2% BSA. Cells were subsequently lysed in 1 ml
of 1 M NaOH, and radioactivity was measured in a gamma counter. Data
are expressed as a percentage of the values for control incubations
containing only labeled ligand. Values are the mean (±SD) of three
independent experiments.
|
|
To learn more about the fate of IL-6 and Hyper-IL-6 upon interaction
with their respective receptors on the cell surface, we performed
internalization studies on HepG2 cells using [125I]IL-6
and [125I]Hyper-IL-6. As shown in Figure 8
A, [125I]IL-6
was rapidly internalized (diamonds). Concomitantly, surface-bound IL-6
molecules were lost (squares). By contrast, when
[125I]Hyper-IL-6 was used in the binding studies,
internalization was impaired (Fig. 8
B). Within 60 min only
10% of the surface-bound Hyper-IL-6 was internalized compared with
45% when IL-6 was used. These results strongly indicate that
internalization of the designer cytokine Hyper-IL-6 was impaired and
that this impairment might contribute to the prolonged and increased
bioactivity of Hyper-IL-6.

View larger version (19K):
[in this window]
[in a new window]
|
FIGURE 8. Internalization of surface-bound [125I]IL-6
(A) and [125I]Hyper-IL-6
(B) in HepG2 cells. Cells were incubated with 100 pM for
2 h at 4°C. Internalization was induced by a temperature shift
to 37°C for the indicated times. Surface-bound protein (squares) was
determined after subjecting the cells to 0.5 M NaCl/HCl, pH 1, for 3
min. Internalized protein (triangles) was measured in the gamma counter
after lysis of the cells in 1 M NaOH. Data are expressed as a
percentage of initial binding of protein at 4°C. Values are the mean
(±SD) of three independent experiments.
|
|
 |
Discussion
|
|---|
In this study we have examined the biologic activities in vitro
and in vivo of a designer cytokine expressed in the yeast Pichia
pastoris consisting of a cytokine fused covalently to its soluble
receptor. We have compared the function of this designer cytokine,
termed Hyper-IL-6, with that of IL-6 alone. Hyper-IL-6 displayed
significantly longer activity in vivo and had a longer plasma half-life
compared with IL-6 alone. Hyper-IL-6 is 10- to 100-fold more active
than the IL-6 counterpart. When transferred to an in vitro system, we
demonstrate that, again, Hyper-IL-6 was more active, and its effects
lasted considerably longer compared with IL-6 alone.
Several important considerations arise from the above-described
findings. We have previously shown in a transgenic mouse model that the
sIL-6R functions as a carrier protein for its ligand IL-6 and causes a
stable IL-6/sIL-6R complex, resulting in a markedly prolonged plasma
half-life of IL-6 (16). The observed reduction of plasma clearance of
IL-6 in the presence of sIL-6R was explained by the size of the
IL-6/sIL-6R complex, which was expected to be cleared by the kidney
less efficiently than IL-6 alone (16). Furthermore, we have
demonstrated that the presence of the sIL-6R in vivo led to a
considerable sensitization of the IL-6 response (16). A similar
mechanism might contribute to the findings observed in this study when
a designer cytokine has been constructed, where IL-6 was fused
covalently to its soluble receptor.
We have demonstrated in this study on HepG2 cells, a higher binding
affinity and an impaired internalization of Hyper-IL-6 compared with
IL-6. HepG2 cells express 450 high affinity sites and 20005000 low
affinity sites for IL-6. Low affinity sites are sites where IL-6 is
bound to the IL-6R (Kd
10-9 M),
whereas high affinity sites are sites where the complex of IL-6 and the
IL-6R is bound to the gp130 signal (Kd
10-11 M) (28, 29). IL-6 has virtually no binding affinity
to the gp130 signal transducer itself (30, 31). From studies performed
previously in our laboratory, it became evident that on hepatoma cells,
gp130 expression exceeds by far expression of the specific IL-6R (29, 32). The ratio of gp130 molecules to IL-6R molecules expressed on
various types of hepatoma cells is around 6:1 as measured by FACS
analysis (H. K. Bos and J. Brakenhoff, unpublished observations).
Hyper-IL-6, being the covalently linked IL-6/sIL-6R complex, should
bind directly to the gp130 signal transducer. This explains why
Hyper-IL-6 can stimulate more gp130 molecules on the cell surface of
hepatocytes than IL-6 alone. Analyzing hepatic haptoglobin expression
in transgenic mice expressing high amounts of the sIL-6R demonstrated
that these animals were significantly sensitized toward exogenously
administered human IL-6. These results also strongly support the idea
of a higher gp130 than IL-6R expression rate on hepatocytes (16). In
summary, these findings are the basis of the understanding that cells
expressing far more gp130 than IL-6R are particularly sensitive to
activation by the IL-6/sIL-6R complex. Hepatocytes and hepatoma cells,
as demonstrated in the studies discussed above, are examples of such
cells.
Cells expressing gp130 on their surface are capable to remove the
IL-6/sIL-6R complex from the circulation by endocytosis (33). It has
been shown that 125I-labeled sIL-6R and IL-6 were
internalized and rapidly degraded within lysosomes by HepG2 cells that
express gp130 molecules (33). We speculate that the differences in
binding affinity and internalization properties between IL-6 and
Hyper-IL-6 are not only caused by the ratio of IL-6R and gp130 signal
transducers expressed on the liver cell. Since IL-6 and sIL-6R were
rapidly internalized molecules (33), the results presented in this
study in Figures 4
C and 6 support the hypothesis that steric
hindrance of the polypeptide linker that connects IL-6 with the sIL-6R
could interfere with the internalization process, leading to decreased
internalization of the molecule on target cells, which, in turn, would
lead to an increased plasma half-life in vivo.
Interestingly, a recent study has investigated whether gp130
internalization and signaling are functionally linked processes (34).
The authors provide evidence that gp130 internalization and signaling
can clearly be dissected. They constructed one set of mutants of gp130
that can internalize and not signal. A second set of mutants can signal
but not internalize. Mutants that lack regions important for signaling
and internalization have lost the ability for both signaling and
internalization (34).
One has to consider the fact that the Hyper-IL-6 molecule has been
produced in the yeast P. pastoris. To date, most
yeast-derived proteins tested in biotechnology have been derived from
Saccharomyces cerevisiae. These proteins show generally a
high mannose glycosylation resulting in the rapid clearance via mannose
receptors in vivo (35). By contrast, the glycosylation of P.
pastoris-derived proteins, which have been used in the present
study, is more similar to that of proteins expressed in mammalian cells
(36) and therefore is more suited for in vivo application. Accordingly,
it has recently been demonstrated that immunization of mice with
recombinant influenza neuraminidase that had been expressed in P.
pastoris protected the animals against a lethal influenza
challenge (37). It remains to be demonstrated, however, whether
Hyper-IL-6 produced in mammalian systems show even longer plasma
half-lives in vivo compared with P. pastoris-derived
Hyper-IL-6. We are currently exploring this possibility in our
laboratory.
In summary we used a designer cytokine consisting of IL-6 covalently
linked to its soluble receptor. Several important points arise from the
presented data. The particular importance of this molecule lies in its
capacity to stimulate cells that express only gp130 on their surface
but not the specific IL-6R and in the applicability of this protein in
vivo. The possible therapeutic use of unlinked IL-6 and sIL-6R is
hampered by the high concentrations of the sIL-6R protein required (12, 17). Therefore, the described Hyper-IL-6 might be especially useful for
future in vivo applications. The physiologic importance of the
activation of the gp130 receptor subunit on various cells has recently
been demonstrated in vitro and in vivo for hemopoietic progenitor cells
(15, 17), for endothelial cells (13), and in the process of liver
regeneration (18). Using Hyper-IL-6, it will be possible to induce
longer stimulation and activation of gp130-expressing cells in vivo in
clinical situations. Apart from possible clinical applications,
Hyper-IL-6 will become an important tool to learn more about cells
expressing only gp130 signal transducers and cell that express low
levels of IL-6R.
 |
Acknowledgments
|
|---|
We thank Sabine Werfel, M.D., for critically reading the
manuscript. C. Trautwein, M.D., is thanked for fruitful
discussions. We thank B. Gilberg for excellent technical assistance and
B. Sayah for excellent help with the artwork.
 |
Footnotes
|
|---|
1 This work was supported by the Deutsche Forschungs-Gemeinschaft (Bonn, Germany), the Naturwissenschaftlidr-Medizinisches Forschungszentrum (Mainz, Germany), and the Stiftung Rheinland Pfalz für Innovation (to M. P. and S.R.-J.). 
2 Address correspondence and reprint requests to Dr. Stefan Rose-John, First Department of Medicine, Division of Pathophysiology, University of Mainz, Obere Zahlbacher Strasse 63, D-55101 Mainz, Germany. E-mail address: 
3 Abbreviations used in this paper: LIF, leukemia inhibitory factor; CNTF, ciliary neurotropic factor; OSM, oncostatin M; CT-1, cardiotropin-1; s, soluble; rh, recombinant human; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
Received for publication September 30, 1997.
Accepted for publication June 1, 1998.
 |
References
|
|---|
-
Taga, T., T. Kishimoto. 1997. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15:797.[Medline]
-
Hibi, M., K. Nakajima, T. Hirano. 1996. IL-6 cytokine family and signal transduction: a model of the cytokine system. J. Mol. Med. 74:1.[Medline]
-
Kishimoto, T., T. Tanaka, K. Yoshida, S. Akira, T. Taga. 1995. Cytokine signal transduction through a homo- or heterodimer of gp130. Ann. NY Acad. Sci. 766:224.[Medline]
-
Ihle, J. N.. 1995. Cytokine receptor signaling. Nature 377:591.[Medline]
-
Schindler, C., J. E. Darnell. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64:621.[Medline]
-
Murakami, M., M. Hibi, N. Nakagawa, T. Nakagawa, K. Yasukawa, K. Yamanishi, T. Taga, T. Kishimoto. 1993. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808.[Abstract/Free Full Text]
-
Stahl, N., T. G. Boulton, T. Farruggella, N. Y. Ip, S. Davis, B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, G. Barbieri, S. Pellegrini, J. N. Ihle, G. D. Yancopoulos. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6ß receptor components. Science 263:92.[Abstract/Free Full Text]
-
Lütticken, C., U. M. Wegenka, J. Yuan, J. Buschmann, C. Schindler, A. Ziemiecki, A. G. Harpur, A. F. Wilks, K. Yasukawa, T. Taga, P. C. Heinrich, F. Horn. 1994. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263:89.[Abstract/Free Full Text]
-
Pennica, D., V. Arce, T. A. Swanson, R. Vejsada, R. A. Pollock, M. Armanini, K. Dudley, H. S. Phillips, A. Rosenthal, A. C. Kato, C. E. Henderson. 1996. Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Neuron 17:63.[Medline]
-
Mosley, B., C. De Imus, D. Friend, N. Boiani, B. Thoma, L. S. Park, D. Cosman. 1996. Dual oncostatin M (OSM) receptors: cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271:32635.[Abstract/Free Full Text]
-
Rose-John, S., P. C. Heinrich. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300:281.
-
Sui, X., K. Tsuji, R. Tanaka, S. Tajima, K. Muraoka, Y. Ebihara, K. Ikebuchi, K. Yasukawa, T. Taga, T. Kishimoto, T. Nakahata. 1995. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 92:2859.[Abstract/Free Full Text]
-
Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, A. Mantovani. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315.[Medline]
-
Hirota, H., H. Kiyama, T. Kishimoto, T. Taga. 1996. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 183:2627.[Abstract/Free Full Text]
-
Peters, M., P. Schirmacher, J. Goldschmitt, M. Odenthal, C. Peschel, H. P. Dienes, E. Fattori, G. Ciliberto, K. H. Meyer zum Büschenfelde, S. Rose-John. 1997. Extramedullary expansion of hematopoietic progenitor cells in IL-6/sIL-6R double transgenic mice. J. Exp. Med. 185:755.[Abstract/Free Full Text]
-
Peters, M., S. Jacobs, M. Ehlers, P. Vollmer, J. Müllberg, E. Wolf, G. Brem, K. H. Meyer zum Büschenfelde, S. Rose-John. 1996. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 183:1399.[Abstract/Free Full Text]
-
Fischer, M., J. Goldschmitt, C. Peschel, K. J. Kallen, J. P. J. Brakenhoff, A. Wollmer, J. Grötzinger, S. Rose-John. 1997. A designer cytokine with high activity on human hematopoietic progenitor cells. Nat. Biotechnol. 15:142.[Medline]
-
Cressman, D. E., L. E. Greenbaum, R. A. DeAngelis, G. Ciliberto, E. E. Furth, V. Poli, R. Taub. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379.[Abstract/Free Full Text]
-
van Dam, M., J. Müllberg, H. Schooltink, T. Stoyan, J. P. Brakenhoff, L. Graeve, P. C. Heinrich, S. Rose-John. 1993. Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules: involvement of two separate domains in receptor binding. J. Biol. Chem. 268:15285.[Abstract/Free Full Text]
-
Rose-John, S., G. Furstenberger, P. Krieg, E. Besemfelder, G. Rincke, F. Marks. 1988. Differential effects of phorbol esters on c-fos and c-myc and ornithine decarboxylase gene expression in mouse skin in vivo. Carcinogenesis 9:831.[Abstract/Free Full Text]
-
Feinberg, A. P., B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6.[Medline]
-
Oppmann, B., T. Stoyan, M. Fischer, N. Voltz, P. März, S. Rose-John. 1996. Alternative assay procedures for cytokines and soluble receptors of the IL-6 family. J. Immunol. Methods 195:153.[Medline]
-
Markwell, M. A. K.. 1982. A new solid state reagent to iodinate proteins. Anal. Biochem. 125:427.[Medline]
-
Dittrich, E., C. R. Haft, L. Muys, P. C. Heinrich, L. Graeve. 1996. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J. Biol. Chem. 271:5487.[Abstract/Free Full Text]
-
Gauldie, J., C. Richards, D. Harnish, P. Lansdorp, H. Baumann. 1987. Interferon ß2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84:7251.[Abstract/Free Full Text]
-
Aarden, L. A., E. R. De Groot, O. L. Schaap, P. M. Lansdorp. 1987. Production of hybridoma growth factor by human monocytes. Eur. J. Immunol. 17:1411.[Medline]
-
Gearing, D. P., S. F. Ziegler, M. R. Comeau, D. Friend, B. Thoma, D. Cosman, L. Park, B. Mosley. 1994. Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Proc. Natl. Acad. Sci. USA 91:1119.[Abstract/Free Full Text]
-
Zohlnhöfer, D., L. Graeve, S. Rose-John, H. Schooltink, E. Dittrich, P. C. Heinrich. 1992. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett. 306:219.[Medline]
-
Rose-John, S., H. Schooltink, D. Lenz, E. Hipp, G. Dufhues, H. Schmitz, X. Schiel, T. Hirano, T. Kishimoto, P. C. Heinrich. 1990. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur. J. Biochem. 190:79.[Medline]
-
Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, T. Kishimoto. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573.[Medline]
-
Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, T. Kishimoto. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149.[Medline]
-
Schooltink, H., H. Schmitz-Van de Leur, P. C. Heinrich, S. Rose-John. 1992. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett. 297:263.[Medline]
-
Graeve, L., T. A. Korolenko, U. Hemmann, O. Weiergräber, E. Dittrich, P. C. Heinrich. 1996. A complex of the soluble interleukin-6 receptor and interleukin-6 is internalized via the signal transducer gp130. FEBS Lett. 399:131.[Medline]
-
Thiel, S., I. Behrmann, E. Dittrich, L. Muys, J. Tavernier, J. Wijdenes, P. C. Heinrich, L. Graeve. 1998. Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway. Biochem. J. 330:47.
-
Marks, D. L., L. J. Kost, S. M. Kuntz, J. C. Romero, N. F. LaRusso. 1991. Hepatic processing of recombinant human renin: mechanisms of uptake and degradation. Am. J. Physiol. 261:349.
-
Grinna, L. S., J. F. Tschopp. 1989. Size distribution and general structural features of N-linked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast 5:107.[Medline]
-
Martinet, W., X. Saelens, T. Deroo, S. Neirynck, R. Contreras, W. Min Jou, W. Fiers. 1997. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem. 247:332.[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
S. Tenhumberg, G. H. Waetzig, A. Chalaris, B. Rabe, D. Seegert, J. Scheller, S. Rose-John, and J. Grotzinger
Structure-guided Optimization of the Interleukin-6 Trans-signaling Antagonist sgp130
J. Biol. Chem.,
October 3, 2008;
283(40):
27200 - 27207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chattopadhyay, E. Tracy, P. Liang, O. Robledo, S. Rose-John, and H. Baumann
Interleukin-31 and Oncostatin-M Mediate Distinct Signaling Reactions and Response Patterns in Lung Epithelial Cells
J. Biol. Chem.,
February 2, 2007;
282(5):
3014 - 3026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Brandl, T. Gluck, P. Hartmann, B. Salzberger, and W. Falk
A designed TLR4/MD-2 complex to capture LPS
Innate Immunity,
August 1, 2005;
11(4):
197 - 206.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Curnow, D. Scheel-Toellner, W. Jenkinson, K. Raza, O. M. Durrani, J. M. Faint, S. Rauz, K. Wloka, D. Pilling, S. Rose-John, et al.
Inhibition of T Cell Apoptosis in the Aqueous Humor of Patients with Uveitis by IL-6/Soluble IL-6 Receptor trans-Signaling
J. Immunol.,
October 15, 2004;
173(8):
5290 - 5297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Brabant, H. Nave, B. Mayr, M. Behrend, V. van Harmelen, and P. Arner
Secretion of Free and Protein-Bound Leptin from Subcutaneous Adipose Tissue of Lean and Obese Women
J. Clin. Endocrinol. Metab.,
August 1, 2002;
87(8):
3966 - 3970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Audet, C. L. Miller, S. Rose-John, J. M. Piret, and C. J. Eaves
Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells
PNAS,
February 13, 2001;
98(4):
1757 - 1762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. GALUN, E. ZEIRA, O. PAPPO, M. PETERS, and S. ROSE-JOHN
Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury
FASEB J,
October 1, 2000;
14(13):
1979 - 1987.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. W. Zandstra, D. A. Lauffenburger, and C. J. Eaves
A ligand-receptor signaling threshold model of stem cell differentiation control: a biologically conserved mechanism applicable to hematopoiesis
Blood,
August 15, 2000;
96(4):
1215 - 1222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ezure, T. Sakamoto, H. Tsuji, J. G. Lunz III, N. Murase, J. J. Fung, and A. J. Demetris
The Development and Compensation of Biliary Cirrhosis in Interleukin-6-Deficient Mice
Am. J. Pathol.,
May 1, 2000;
156(5):
1627 - 1639.
[Abstract]
[Full Text]
[PDF]
|
 |
|